308
Views
11
CrossRef citations to date
0
Altmetric
Review

Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 495-508 | Received 20 Mar 2020, Accepted 07 May 2020, Published online: 18 Jun 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Martina Bortolami, Daniele Rocco, Antonella Messore, Roberto Di Santo, Roberta Costi, Valentina Noemi Madia, Luigi Scipione & Fabiana Pandolfi. (2021) Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present). Expert Opinion on Therapeutic Patents 31:5, pages 399-420.
Read now

Articles from other publishers (10)

Min-Soo Kim, Jungim Kim, Kang-In Lee, Hye Jin Kim, Hyungjun Kim, Donghwan Kim & Ki-Sun Park. (2023) Magnolia officinalis bark extract improves depressive-like behavior in DSS-induced colitis mice. Journal of Functional Foods 108, pages 105775.
Crossref
Josselin Corzo-Gómez, Ofir Picazo, Manuela Castellanos-Pérez & Alfredo Briones-Aranda. (2023) Systematic Review of the Serotonergic System in the Pathophysiology of Severe Dengue: The Theory of Thrombocytopenia and Vascular Extravasation. Mini-Reviews in Medicinal Chemistry 23:2, pages 230-243.
Crossref
Ayame Saito, Sadia Alvi, Celine Valant, Arthur Christopoulos, Simona E. Carbone & Daniel P. Poole. (2023) Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders. British Journal of Pharmacology.
Crossref
Candice M. Roux, Marianne Leger & Thomas Freret. (2021) Memory Disorders Related to Hippocampal Function: The Interest of 5-HT4Rs Targeting. International Journal of Molecular Sciences 22:21, pages 12082.
Crossref
Line Séguy, Léna Guyon, Manon Maurel, Pascal Verdié, Audrey Davis, Sophie Corvaisier, Vincent Lisowski, Patrick Dallemagne, Anne-Claire Groo & Aurélie Malzert-Fréon. (2021) Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment. Pharmaceutics 13:10, pages 1626.
Crossref
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Durga Malleshwari Kancharla, Srinivasa Rao Ravella, Narsimha Bogaraju, Vanaja Reddy Middekadi, Ramkumar Subramanian, Raghava Choudary Palacharla, Vijay Benade, Nageswararao Muddana, Renny Abraham, Rajesh Babu Medapati, Jagadeesh Babu Thentu, Venkat Reddy Mekala, Surendra Petlu, Bujji Babu Lingavarapu, Sivasekhar Yarra, Narendra Kagita, Vinod Kumar Goyal, Santosh Kumar Pandey & Venkat Jasti. (2021) Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT 4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease . Journal of Medicinal Chemistry 64:15, pages 10641-10665.
Crossref
Patrick Dallemagne & Christophe Rochais. (2021) 5-HT4R modulators: a patent landscape. Pharmaceutical Patent Analyst.
Crossref
Alejandro Castro-Alvarez, Emigdio Chávez-Ángel & Ronald Nelson. (2021) Understanding the Molecular Basis of 5-HT4 Receptor Partial Agonists through 3D-QSAR Studies. International Journal of Molecular Sciences 22:7, pages 3602.
Crossref
Amin Charousaei, Mohammad Nasehi, Vahab Babapour, Salar Vaseghi & Mohammad-Reza Zarrindast. (2021) The effect of 5-HT4 serotonin receptors in the CA3 hippocampal region on D-AP5-induced anxiolytic-like effects: Isobolographic analyses. Behavioural Brain Research 397, pages 112933.
Crossref
Fotini Moschona, Ioanna Savvopoulou, Maria Tsitopoulou, Despoina Tataraki & Gerasimos Rassias. (2020) Epoxide Syntheses and Ring-Opening Reactions in Drug Development. Catalysts 10:10, pages 1117.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.